TABLE 2.
Summary of demographic characteristics of subjects
| Study | No. of subjects enrolled | Agea (yr) | Wta (kg) | Body mass indexa (kg/m2) | No. C/B/H/Ob | No. of subjects evaluable for pharmacokinetics/for safety |
|---|---|---|---|---|---|---|
| Study A | ||||||
| Voriconazole/ritonavir (400 mg) | 17 | 31 (19-52) | 77.6 (62.0-88.0) | 25.4 (19.6-29.4) | 5/0/11/1 | 14/17 |
| Placebo/ritonavir (400 mg) | 17 | 31 (19-52) | 76.1 (60.0-90.0) | 25.8 (21.3-29.4) | 4/1/12/0 | 15/17 |
| Study B | ||||||
| Voriconazole/ritonavir (100 mg) | 17 | 40 (26-54) | 79.9 (64.9-94.8) | 26.6 (23.0-29.1) | 1/0/16/0 | 17/17 |
a
Mean (range).
b
C, Caucasian; B, black; H, Hispanic; O, other.